Greenridge analyst William Gregozeski lowered the firm’s price target on EUDA Health (EUDA) to $2.75 from $6 and keeps a Buy rating on the shares. The firm updated its model for a reduction of Helixe bottles sold in 2026, decreasing to 50,000 from 105,000, which reduced its revenue estimate to $27.23M from $43.05M. It also added in the 12.5M shares that were issued in late February, which had a dilutive effect on its EPS estimates, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- EUDA Health Repurchases Streeterville Warrant and Amends Charter to Clarify Share Actions
- EUDA Health announces repurchase, cancellation of Streeterville warrant
- EUDA Health Raises $3.75 Million and Retires Dilutive Warrant in February 2026 Capital Moves
- EUDA Health Lowers Streeterville Warrant Exercise Price to Align With Market Conditions
- EUDA Health announces second amendment to Streeterville warrant agreement